Lead Product(s) : Histamine Dihydrochloride,Interleukin 2
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Delbert Lab
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.
Product Name : Ceplene
Product Type : Amino Acid
Upfront Cash : Undisclosed
November 18, 2022
Lead Product(s) : Histamine Dihydrochloride,Interleukin 2
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Delbert Lab
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myelomonocytic, Chronic.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
February 02, 2017
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Karolinska University Hospital | Nordic MDS Group | Sahlgrenska University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen
Details : Histamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinitis, Allergic.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
November 01, 2012
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : EpiCept
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
May 05, 2011
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : EpiCept
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : EpiCept
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Histamine Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myelodysplastic Syndromes.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
March 29, 2011
Lead Product(s) : Histamine Dihydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : EpiCept
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
